Functional comparison between the BuMA Supreme biodegradable polymer sirolimus-eluting stent and a durable polymer zotarolimus-eluting coronary stent using quantitative flow ratio: PIONEER QFR substudy

Taku Asano1,2, MD; Yuki Katagiri1, MD; Carlos Collet1, MD; Erhan Tenekecioglu3, MD; Yosuke Miyazaki3, MD, PhD; Yohei Sotomi1, MD; Giovanni Amoroso4, MD, PhD; Adel Aminian5, MD; Salvatore Brugaletta6, MD, PhD; Mathias Vrolix7, MD; Rosana Hernandez-Antolín8, MD, PhD; Pim van de Harst9,10, MD, PhD; Andres Iñiguez11, MD, PhD; Luc Janssens12, MD; Pieter C. Smits13, MD, PhD; Joanna Wykrzykowska1, MD, PhD; Vasco Gama Ribeiro14, MD; Helder Pereira15, MD; Pedro Canas da Silva16, MD; Jan J. Piek1, MD, PhD; Johan H.C. Reiber17, PhD; Clemens von Birgelen18, MD, PhD; Manel Sabaté6, MD, PhD; Yoshinobu Onuma3,19*, MD, PhD; Patrick W. Serruys20, MD, PhD

1. Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; 2. Department of Cardiology, St. Luke’s International Hospital, Tokyo, Japan; 3. Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands; 4. Onze Lieve Vrouwe Gasthu

Aims: Quantitative flow ratio (QFR) based on three-dimensional quantitative coronary angiography (3D-QCA) is a novel method to assess physiological functionality after treatment with sten

Sign in to read and download the full article

Login Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

clinical researchfractional flow reserveother techniquestable angina

Share on Facebook Share on Twitter Share on Linkedin

Read next article

Impact of bleeding assessment and adjudication methodology on event rates and clinical trial outcomes: insights from the HORIZONS-AMI trial